iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial
Yabe, Daisuke, Iizuka, Katsumi, Baxter, Mike, Watanabe, Daisuke, Kaneto, Hideaki
Published in Journal of diabetes investigation (01.11.2021)
Published in Journal of diabetes investigation (01.11.2021)
Get full text
Journal Article
Fixed‐ratio combination of basal insulin and glucagon‐like peptide‐1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge
Kaneto, Hideaki, Koshida, Ryusuke, Baxter, Mike
Published in Diabetes, obesity & metabolism (01.09.2020)
Published in Diabetes, obesity & metabolism (01.09.2020)
Get full text
Journal Article
Glycaemic variability: The under‐recognized therapeutic target in type 1 diabetes care
Wilmot, Emma G., Choudhary, Pratik, Leelarathna, Lalantha, Baxter, Mike
Published in Diabetes, obesity & metabolism (01.12.2019)
Published in Diabetes, obesity & metabolism (01.12.2019)
Get full text
Journal Article
Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL)
Kaneto, Hideaki, Baxter, Mike, Takahashi, Yoko, Terauchi, Yasuo
Published in Advances in therapy (01.12.2022)
Published in Advances in therapy (01.12.2022)
Get full text
Journal Article
Benefits of the fixed‐ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time‐to‐control analysis of the LixiLan JP phase 3 trials
Terauchi, Yasuo, Yabe, Daisuke, Kaneto, Hideaki, Amano, Atsushi, Baxter, Mike, Watanabe, Daisuke, Watada, Hirotaka, Inagaki, Nobuya
Published in Diabetes, obesity & metabolism (01.09.2020)
Published in Diabetes, obesity & metabolism (01.09.2020)
Get full text
Journal Article
Benefits of the fixed‐ratio combination of insulin glargine 100units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time‐to‐control analysis of the LixiLan JP phase 3 trials
Terauchi, Yasuo, Yabe, Daisuke, Kaneto, Hideaki, Amano, Atsushi, Baxter, Mike, Watanabe, Daisuke, Watada, Hirotaka, Inagaki, Nobuya
Published in Diabetes, obesity & metabolism (01.09.2020)
Published in Diabetes, obesity & metabolism (01.09.2020)
Get full text
Journal Article
A Real-World, Observational Study of the Initiation, Use, and Effectiveness of Basal-Bolus or Premixed Insulin in Japanese People with Type 2 Diabetes
Miyoshi, Hideaki, Baxter, Mike, Kimura, Takeshi, Hattori, Masakatsu, Morimoto, Yukiko, Marinkovich, Dion, Tamiwa, Masami, Hirose, Takahisa
Published in Diabetes therapy (01.05.2021)
Published in Diabetes therapy (01.05.2021)
Get full text
Journal Article
Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK
McCrimmon, Rory J., Falla, Edel, Sha, Jo Zhou, Alsaleh, Abdul Jabbar Omar, Lew, Elisheva, Hudson, Richard, Baxter, Mike, Palmer, Karen
Published in Diabetes therapy (01.12.2021)
Published in Diabetes therapy (01.12.2021)
Get full text
Journal Article